Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipatasertib plus Palbociclib and Fulvestrant in HR+ HER2- Breast Cancer
NCT04060862Phase 1Terminated
- Sponsor
- Roche
- Start
- Nov 2019
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 1, randomised, double-blind trial in breast cancer comparing Ipatasertib + Palbociclib + Fulvestrant with Placebo + Palbociclib + Fulvestrant (2 arms). Primary endpoint: Progression-Free Survival at 36 months. Started Nov 2019; status: terminated.
02
Drugs
ipatasertib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04060862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04060862.